Sleep disruption and its psychological treatment in young people at risk of psychosis: A peer methods qualitative evaluation.

Br J Clin PsycholJul 6, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Felicity Waite, Steven Evans, Abreen Rebello et al.

✦ AI-curated · Sources linked

In 30 seconds

This peer-methods qualitative study explored how young people at risk of psychosis experienced sleep problems and psychological sleep therapy. Researchers used semi-structured interviews and reflexive thematic analysis with 16 participants in the SleepWell Trial; 10 had received the 12-week therapy. Four themes concerned barriers to mental health care, the perceived connection between sleep and mental health, the value of flexible therapy, and wider benefits of improved sleep. Participants described better sleep alongside improvements in mood, confidence, voices, fears and everyday life. These accounts indicate perceived benefits, rather than establishing treatment efficacy.

Key findings

  • Participants described rejection and invalidation when seeking mental health care, contributing to hopelessness and resignation.
  • Interviewees viewed sleep disruption and other mental health difficulties as closely connected.
  • Flexible delivery and a clear therapeutic focus were valued and supported ownership, engagement and hope.
  • Participants reported better sleep alongside fewer voices and fears, improved mood and confidence, and benefits in everyday life.

Why it matters

The interviews highlight that sleep problems are experienced within a broader context of mental health difficulties and barriers to care. Participants valued a focused, adaptable approach and described benefits extending beyond sleep. These perspectives can inform understanding of what young people may find acceptable and helpful, while qualitative accounts cannot determine how consistently such benefits occur.

What to keep in mind

This was a qualitative interview study of 16 trial participants, including 10 who received therapy; participant accounts do not establish treatment efficacy or the frequency of reported benefits.

Source

Published in Br J Clin Psychol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.